27 results about "Arsenic trioxide" patented technology

Described herein are methods of treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in need thereof. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas, and solid tumors including glioblastoma multiforme and breast cancer. Also described herein are oral pharmaceutical formulations comprising lyophilized compositions comprising arsenic and methods for lyophilizing arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and treating a subject with malignancies using the oral formulation.

A cobalt-chromium alloy stent comprising several main body units, wherein each main body unit is composed of several supporting rings connected by flexible ribs and the adjacent main body units are connected by several connecting ribs. A drug eluting stent comprising the cobalt-chromium alloy stent and a drug coating containing arsenic trioxide and tacrolimus. The drug release curves of the two composite drugs of arsenic trioxide and tacrolimus used in the present invention are adjusted, so that the inflammatory response of vascular endothelial cells and the proliferation behavior of vascular smooth muscle cells are effectively inhibited, and the vascular restenosis rate is reduced.

The utility model discloses arsenic trioxide grading and bagging equipment which comprises a stock bin and a grading device communicated with the stock bin, the grading device comprises a supporting frame, a device body and a screening assembly, a product discharging port is formed in the bottom of the device body, a long-neck ton bag is arranged below the discharging port, and a fixing plate and a rotating plate are erected below the supporting frame. A bag opening clamping assembly is hinged to the fixing plate, an opening rolling assembly is hinged to the rotating plate, the bag opening clamping assembly comprises a semicircular clamping jaw, a first connecting rod and a first air cylinder connected with the first connecting rod, the semicircular clamping jaw is opposite to the tail end of the discharging opening, and the opening rolling assembly comprises a pressing jaw capable of being buckled, a second connecting rod and a second air cylinder connected with the second connecting rod. And the pressing claw is lower than the discharge hole. Through the arrangement of the grading device, the bag opening clamping assembly and the opening rolling assembly, secondary grading before bagging, automatic bag opening fixing and automatic bag opening tightening after bagging are achieved, manual intervention is little, generation and dissipation of flying dust are effectively avoided, and the automatic bagging machine has the advantages of being controllable in quality and high in operation safety.

The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation.

The invention relates to the technical field of medicines, in particular to red date arsenic oxide derived carbon dots as well as a preparation method and application thereof. According to the carbon dots, natural biomass red dates serve as a carbon source, traditional Chinese medicine arsenic oxide serves as an arsenic source, green synthesis is conducted through a hydrothermal method or a pyrolysis method, and subsequent research is conducted on the carbon dots synthesized through the pyrolysis method. Through characterization, the material has a uniform spherical morphology, the particle size is about 1.63 nm, and it is proved that arsenic atoms are successfully doped. The carbon dots have excellent stability in a physiological environment, and have low toxicity and high biocompatibility. In an in-vitro experiment, the apoptosis of the HL-60 acute promyelocytic leukemia can be remarkably induced by inducing ros, promoting differentiation and reducing the protein level of PML-RAR alpha. In in-vivo experiments, APL tumor growth is inhibited, the tumor inhibition rate reaches up to 66.6%, and obvious damage to liver and kidney functions is avoided. The invention overcomes the defects of strong toxicity, inconvenient administration and the like of the existing arsenic trioxide (ATO) for treating APL, provides a novel high-efficiency and low-toxicity therapeutic drug for acute promyelocytic leukemia, and has important clinical transformation value.

A degradable biomedical magnesium alloy drug-eluting vascular stent and a preparation method. With the total weight of a magnesium alloy being 100% for calculation, the magnesium alloy comprises the following components in percentage by weight: 3.0-6.0% of Gd, 2.5-5.5% of Y, 1.0-3.0% of Li, 0.3-1.0% of Zn, 0.2-1.0% of Zr, and the balance being Mg. The stent has good radial support strength and strain dispersion capability by means of finite element design. After a protective coating is used, the corrosion resistance of the magnesium alloy stent is greatly improved. An arsenic trioxide / rapamycin and tacrolimus composite drug sustained-release system is used to fully adapt to the damage repair process of blood vessels. An implantation result of large animals shows that the vascular stent system has a good anti-restenosis treatment effect.

The utility model discloses a pneumatic conveying device for arsenic trioxide, which structurally comprises a discharging bin arranged at a low position, a finished product storage tank arranged at a high position, a conveying pipeline communicated with the discharging bin and the finished product storage tank, and a first high-pressure air pipe communicated with the end, close to the discharging bin, of the conveying pipeline and used for conveying. The bottom of the discharging bin is communicated with a second high-pressure air pipe with the annular tail end and provided with a plurality of flexible air pipes, a pressure relief opening connected with a pressure relief pipe is formed in the side wall, close to the feeding opening, of the finished product storage tank, the tail end of the pressure relief pipe extends to the bottom of the absorption barrel, and liquid is contained in the absorption barrel. Through the arrangement of the second high-pressure gas pipe and the pressure relief pipe, arsenic trioxide powder enters the conveying pipeline in a fluidized form, gas which is higher in pressure and is completely used for conveying the fluidized powder can be introduced into the first high-pressure gas pipe, the loss of the conveying pressure is greatly reduced, and the conveying height is increased; the problems that an existing pneumatic conveying device is large in conveying pressure loss, insufficient in conveying height, prone to blockage of a conveying pipeline and the like are effectively solved.

The present application relates to a new use of Dihydroquercetin for preventing and treating cardiac toxicity induced by arsenic trioxide, and belongs to the technical field of medicine. In order to solve the problem that the prior art lacks effective treatment means for cardiac toxicity induced by ATO, the present application provides a new use of Dihydroquercetin for preventing and treating cardiac toxicity induced by arsenic trioxide, that is, the application of Dihydroquercetin in the preparation of a medicine for preventing and treating cardiac toxicity induced by arsenic trioxide. The present application proves through experiments that Dihydroquercetin can alleviate cardiac toxicity induced by ATO in multiple ways, including alleviating ATO-induced apoptosis, ferroptosis, oxidative stress, mitochondrial dysfunction and DNA damage. The present application finds that Dihydroquercetin has an excellent effect of preventing and treating cardiac toxicity induced by arsenic trioxide, provides a new strategy for improving the safety of arsenic trioxide, provides an embedding point for preparing a new medicine for preventing and treating cardiac toxicity induced by arsenic trioxide, and has an important clinical application prospect.

The invention provides a pharmaceutical composition for degrading a PML-RAR alpha protein drug-resistant mutant and application of the pharmaceutical composition. The pharmaceutical composition comprises interferon and arsenic trioxide. According to the composition disclosed by the invention, HeLa cells or NB4 cells for expressing the drug-resistant mutant of the PML-RAR alpha fusion protein are jointly treated by using interferon and arsenic trioxide, so that the degradation of the drug-resistant mutant of the PML-RAR alpha fusion protein is specifically induced. The invention provides help for researching the degradation mechanism of the PML-RAR alpha fusion protein drug-resistant mutant and developing drugs for patients with arsenic drug-resistant APL.

The invention provides a preparation method of nanoscale arsenic particles, and belongs to the technical field of nano materials. The invention provides a preparation method of nanoscale arsenic particles, which comprises the following steps: mixing arsenic trioxide and concentrated hydrochloric acid with the mass fraction of 10-35% for double decomposition reaction to obtain a hydrochloric acid aqueous solution of arsenic trichloride; under the oxygen-free condition, arsenic hydride-containing gas is introduced into the hydrochloric acid aqueous solution of arsenic trichloride for a neutralization reaction, the nanoscale arsenic particles are obtained, and the particle size of a single arsenic particle is 65-85 nm. According to the method, safe and practical nanoscale arsenic particles can be obtained by using the arsenic hydride-containing gas and the hydrochloric acid aqueous solution of arsenic trichloride at normal temperature and normal pressure, only water is generated in the neutralization reaction, extra waste residues and waste liquid are not generated, and the method is simple in equipment, less in maintenance, short in process, low in energy consumption and few in by-products.

The invention relates to the technical field of biology, in particular to arsenic trioxide combined copper ions, a carrier and application. Recognition and killing of tumors by inducing tumor cells ICD and activating an autoimmune system are one of effective strategies for solving clinical PD-1 antibody application pain spots at present. The invention clarifies the mechanism and curative effect of inducing tumor cells to generate ICD by combining low-concentration ATO with Cu < 2 + > and sensitizing PD-1 antibody immunotherapy, side effects possibly caused by large-dose application of ATO are avoided to a certain extent, and a new strategy is provided for improving the clinical benefit of the PD-1 antibody and improving the clinical practicability of ATO.

The invention discloses an application of arsenic trioxide in preparation of a medicine for reversing cetuximab resistance of head and neck squamous cell carcinoma, arsenic trioxide ATO can be specifically combined with CLIP170, the ATO targets a zinc finger structure region of the CLIP170, arsenic trioxide can reverse and treat the cetuximab resistance of HNSCC by taking interference on the zinc finger structure of the CLIP170 as a target spot, the sensitivity of the cetuximab resistance of HNSCC is improved, and the application of arsenic trioxide in preparation of a medicine for reversing cetuximab resistance of HNSCC is realized. And a new thought is provided for attacking HNSCC cetuximab resistance chemosensitization.

This invention discloses a nasal administration of traditional Chinese medicine composition for adjuvant cancer treatment and its preparation method, comprising the following raw materials in parts by weight: each part is 1 gram, including 5-10 parts of Phellinus linteus, 4-9 parts of Ganoderma lucidum, 5-10 parts of Panax notoginseng, 3-8 parts of Cremastra appendiculata, 4-9 parts of Ligustrum lucidum, 1-5 parts of Cordyceps sinensis, 8-14 parts of Prunus persica, 2-5 parts of scallion, 3-15 parts of bitter almond, 8-15 parts of jujube, 3-6 parts of pepper, 50-60 parts of gypsum, 2-8 parts of Croton tiglium, 0.2-0.5 parts of arsenic trioxide, 1-5 parts of calomel, and 2-4 parts of ginger. This invention utilizes nasal inhalation via the mucous membrane for administration, achieving effects such as inhibiting tumor cells, enhancing the body's immune function, shortening the treatment cycle, and reducing side effects, making it suitable for adjuvant treatment of various cancers.

Provided herein are methods and compositions for the treatment of cancers with D-VC and arsenic trioxide. In some aspects, cancers for treatment according to the embodiments include cancers with increased GLUT1 expression and / or comprise KRAS mutation.

The application discloses an antitumor composition of arsenic trioxide and artesunate for enhancing the drug efficacy of arsenic trioxide, and discloses GA modified pH responsive arsenic trioxide-artesunate double-drug nanoliposome including the composition, the double-drug nanoliposome including glycyrrhetinic acid-polyethylene glycol-hydrazone-distearyphosphatidyl ethanolamine polymer, cholesterol, artesunate and calcium arsenate nanoparticles; the glycyrrhetinic acid-polyethylene glycol-hydrazone-distearyphosphatidyl ethanolamine and cholesterol form nanoliposome, and the nanoliposome is loaded with artesunate and calcium arsenate nanoparticles; the calcium arsenate nanoparticles contain arsenic trioxide, and a preparation method and application in preparing antitumor drugs are disclosed. The application first co-loads the highly toxic traditional Chinese medicine arsenic trioxide and artesunate to play a synergistic effect, realizes the attenuation and efficiency enhancement of arsenic trioxide through targeted modification delivery and tumor microenvironment response release, and has a good clinical application prospect.

The invention discloses a medicine for inhibiting tumor cell activity by combining arsenic trioxide and bupivacaine and application of the medicine, and belongs to the technical field of biological medicine. The medicine comprises arsenic trioxide and bupivacaine, the concentration of the arsenic trioxide is 2 microns, and the concentration of the bupivacaine is 200 microns. The solvent is a complete cell culture medium. The complete cell culture medium is prepared from 89vol% of DMEM (dulbecco modified eagle medium) high-glucose culture medium, 10vol% of fetal calf serum and 1vol% of penicillin-streptomycin solution. The combination of arsenic trioxide and bupivacaine can significantly inhibit proliferation and migration of liver cancer cells and has a synergistic anti-liver cancer effect, the proliferation and migration functions of the liver cancer cells can be significantly inhibited by single use of an ineffective small dose of arsenic trioxide and bupivacaine, and the application dose of arsenic trioxide can be reduced so as to reduce the toxic and side effects of arsenic trioxide.

The application discloses a uniform feeding equipment for coarse arsenic, relates to the technical field of arsenic trioxide feeding devices, and comprises a shell in a back shape, wherein the two ends of the shell are in arc shapes, the back-shaped shell extends into a silicon carbide hearth and is in non-contact with the inner wall of the hearth, a conveying device is arranged in the shell, the conveying device comprises two conveying wheels and a conveying belt, the two conveying wheels are arranged at the two ends of the shell, the conveying belt is sleeved on the two conveying wheels, a spacing is formed between the conveying belt and the shell, and a pushing block for pushing coarse arsenic materials to move is arranged on the conveying belt; the upper end of the shell is provided with a feeding port, and the lower end of the shell is provided with a discharging port. The application solves the problems of non-uniform feeding of a traditional hopper and scratching of the silicon carbide hearth, and after the application is used, not only is uniform feeding realized, but also the scratching of the hearth is effectively reduced, and very positive practical effects are achieved.

Provided herein are methods and compositions for the treatment of cancers with D-VC and arsenic trioxide. In some aspects, cancers for treatment according to the embodiments include cancers with increased GLUT1 expression and / or comprise KRAS mutation.

The invention discloses an arsenic in-situ growth-metal organic framework material which is arsenic oxide nanoparticles formed in situ on the surface of a metal organic framework material by performing ligand exchange on an arsenic compound and the metal organic framework material, the arsenic compound is selected from sodium arsenite, disodium arsenate heptahydrate, arsenic trioxide and the like; the metal organic framework material is selected from ZIF-8 and the like. The invention also discloses bionic nano-particles for in-situ growth of arsenic. The bionic nano-particles are formed by coating an arsenic in-situ growth-metal organic framework material with a cell membrane. The invention further discloses application of the arsenic in-situ growth-metal organic framework material and the bionic nanoparticles in preparation of drugs for treating cancers. The arsenic in-situ growth-metal organic framework material disclosed by the invention is bionic nano-enzyme with enzyme-like activity and dual epigenetic regulation and control effects, and is uniform in morphology and relatively small in particle size; and due to cell membrane coating, the bone marrow targeting property is realized, the problem of insufficient targeting property of an arsenic compound is solved, and the tumor immunotherapy effect is enhanced.

The invention relates to powder for treating haemorrhoids and a preparation method thereof, the powder comprises the following raw materials: arsenic, dried alum, realgar and venenum bufonis, the medicines are ground into 80-mesh fine powder, the ground raw materials are respectively heated, and then the heated raw materials are cooled and uniformly mixed. According to the traditional Chinese medicine composition disclosed by the invention, through a specific ratio and a scientific preparation process, all the medicinal components are mutually cooperated, and the treatment effect of the medicine is enhanced. Meanwhile, the preparation method is relatively simple to operate and convenient for industrial production, and the prepared powder is convenient to carry and use.

The invention discloses a method for extracting rhenium from a rhenium-containing solution difficult to treat. The method comprises the steps of transformation pretreatment, precise filtration, extraction, reverse extraction, concentration and crystallization. The method for extracting the rhenium from the rhenium-containing solution difficult to treat comprises the steps of transformation pretreatment and precise filtration, the transformation pretreatment utilizes the principle that the solubility of arsenic trioxide is increased along with temperature rise, the rhenium-containing solution difficult to treat is subjected to heating treatment, so that organic impurities in a liquid phase are removed, and the rhenium is extracted from the rhenium-containing solution difficult to treat. Meanwhile, suspended fine-particle arsenic trioxide impurities difficult to filter are dissolved and enter a liquid phase, the heated liquid is cooled and left to stand, supersaturated arsenic trioxide impurities in the liquid phase are separated out again, the purpose of changing the crystal form of arsenic trioxide is achieved, then arsenic trioxide with the changed crystal form is removed through precise filtration, and purified liquid is obtained; due to the fact that suspended fine-particle arsenic trioxide impurities difficult to filter and organic impurities are removed in the process at the same time, an emulsified third phase cannot occur in the extraction process, and rhenium can be well recycled.

The utility model provides arsenic trioxide purification treatment equipment which comprises a purification furnace, the purification furnace is provided with a first inlet and a first outlet, and the purification furnace is used for purifying coarse arsenic trioxide in the purification furnace to obtain purified flue gas; the sedimentation device is communicated with the purification furnace through a first inlet and is used for carrying out sedimentation treatment on the purified flue gas entering the inner cavity of the sedimentation device so as to obtain sedimentation flue gas; the cooling device is communicated with the settling device and is used for reducing the temperature of settling flue gas flowing into the cooling device from the inner cavity of the settling device to a second preset temperature so as to obtain arsenic trioxide crystals. According to the present invention, with the equipment, the problem that the arsenic trioxide product content in the product is not stable due to the fact that the arsenic trioxide product content is not stable is solved, and the purity of the obtained arsenic trioxide is high and can achieve 99.5%.

The present invention relates to a liquid pharmaceutical composition comprising totally dissolved arsenic trioxide, at least one solubilizing agent selected from the metal-alkali acetates and metal-alkali lactates, and a solvent system which comprises a non-ionic surfactant and propylene glycol. The invention also relates to pharmaceutical capsule comprising the liquid composition of the invention. The invention further relates to said liquid pharmaceutical composition or said pharmaceutical capsule for use in the treatment of cancer or autoimmune diseases.

The invention provides a preparation method of all-transretinoic acid and arsenic trioxide composite nano sustained-release microspheres, which comprises the following steps: a, adding albumin and L-reduced glutathione into deionized water, and carrying out reduction reaction on disulfide bonds in albumin molecules to obtain a reduced albumin aqueous solution; b, taking a sodium hydroxide solution of ATO, and then adding the sodium hydroxide solution of ATO into the reductive albumin aqueous solution obtained in the step a to obtain an ATO-albumin solution; c, ATRA is added into absolute ethyl alcohol and stirred, and an ethyl alcohol solution of ATRA is obtained; d, dropwise adding the ATRA ethanol solution obtained in the step c into the ATO-albumin solution obtained in the step b by using a micro-injection pump to obtain an ATRA and ATO composite nano sustained-release microsphere crude product; and e, centrifuging the crude product, cleaning with deionized water, and freeze-drying to obtain the microsphere product. The preparation method of the product is rapid, simple and convenient, the targeting property is strong, the effect of resisting tumor growth and metastasis of the medicine can be obviously enhanced, and the biological safety is good.

The invention relates to the technical field of biology, in particular to arsenic trioxide combined copper ions, a carrier and application. Recognition and killing of tumors by inducing tumor cells ICD and activating an autoimmune system are one of effective strategies for solving clinical PD-1 antibody application pain spots at present. The invention clarifies the mechanism and curative effect of inducing tumor cells to generate ICD by combining low-concentration ATO with Cu < 2 + > and sensitizing PD-1 antibody immunotherapy, side effects possibly caused by large-dose application of ATO are avoided to a certain extent, and a new strategy is provided for improving the clinical benefit of the PD-1 antibody and improving the clinical practicability of ATO.

The invention discloses a nucleotide for inhibiting expression products of five RNAs (Ribonucleic Acid) related to MAN1A2 and application of the nucleotide, the sequence of the nucleotide is characterized by being AGAAAUUCAGAAGAAA or GUCCAAGAAAUGAAGAUAA and a complementary sequence thereof, and the nucleotide can be used for specifically weakening the expression of mRNA (Messenger Ribonucleic Acid) of the MAN1A2 gene and four related circular RNAs. Experiments prove that the nucleic acid molecule can achieve a gene silencing effect of MAN1A2 mRNA and four related circular RNAs in a human non-small cell lung cancer cell line A549, so that the survival rate of lung cancer cells is remarkably reduced, and when the nucleic acid molecule and a tumor treatment drug arsenic trioxide are jointly applied, a synergistic effect can be generated, so that the survival rate of tumor cells is reduced by 1.3-1.4 times.

The invention provides a method for preparing elemental arsenic by continuous reduction of arsenic trioxide, which comprises the following steps: S1, pelletizing arsenic trioxide powder to obtain a spherical material; s2, heating and distilling the spherical material to generate distilled gas; s3, heating the distillation gas and hydrogen to carry out reduction reaction; s4, pyrolyzing the reduced gas to remove byproducts; and S5, condensing the gas subjected to pyrolysis treatment, and collecting elemental arsenic. According to the method and equipment provided by the invention, the spherical material prepared from the arsenic trioxide powder is heated, distilled, converted into the gaseous state and then reacted with hydrogen, the whole reduction process is a gas-gas reaction, the advantages of active molecular movement and sufficient reaction in the gaseous state are utilized, efficient reduction of arsenic trioxide is realized, the reaction can be continuously carried out, and the production efficiency is improved. And the efficiency is high, the requirement for equipment is low, and arsenic powder output with the ton-level yield can be achieved.